close
close

An overview of viral proteins of SARS-CoV-2 with relevance for improved diagnostic and therapeutic platforms

REVIEW article

Front. Virol.

Section Viral diversification and evolution

Volume 4 – 2024 |

doi: 10.3389/fviro.2024.1399993

This article is part of the research topic Impact of the SARS-CoV-2 pandemic on the evolution and epidemiology of other viruses Show all 3 articles

Provisionally accepted

  • 1

    GeneOne Life Science, Inc., Seoul, Republic of Korea

  • 2

    Langone Medical Center, New York University, New York City, New York, USA

  • 3

    The Wistar Institute, Philadelphia, Pennsylvania, USA

  • 4

    NanoBio Diagnostics, West Chester, PA-19382, United States

The final, formatted version of the article will be published shortly.

    Over the past 25 years, there have been outbreaks of disease in humans worldwide due to three different coronaviruses. Both the SARS-CoV outbreak in 2003 and the MERS-CoV outbreak in 2013 resulted in low overall fatalities, partly due to inefficient human-to-human transmission of each virus. In contrast, SARS-CoV-2, which emerged in 2019, was highly efficient at human-to-human transmission and caused a global pandemic with millions of victims. Zoonotic transmission of viruses, including the three coronaviruses, represents an ongoing threat that cannot be ignored. In this review, we focused on the areas of diagnostics and therapeutics and used SARS-CoV-2 as a model. In particular, we selected proteins associated with the virus particles as targets and discussed various platform technologies. These findings have the potential to advance the development of more effective therapeutics and vaccines not only for SARS-CoV-2 but also for future viral pandemics, thus contributing to global health on a larger scale.

    Keywords:
    SARS-CoV-2 Viral structural proteins, infections and variants, clinical diagnostics, therapeutics, vaccine development

    Receive:
    March 12, 2024;
    Accepted:
    09.September 2024.

    Copyright:
    © 2024 Chung, Irudayaraj, Lallow, Xu, Xu, Park, Montaner, Kudchodkar, Srinivasan, and Muthumani. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). Use, distribution, or reproduction in other forums is permitted provided the original author(s) or licensor are credited and the original publication in this journal is cited in accordance with accepted academic practice. Use, distribution, or reproduction not in accordance with these terms is not permitted.

    * Correspondence:

    Kar Muthumani, GeneOne Life Science, Inc., Seoul, 06060, Republic of Korea

    Disclaimer:
    All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, editors, and reviewers. No warranty or endorsement is made by the publisher for any product reviewed in this article or for any claims made by its manufacturer.

    You may also like...